101 related articles for article (PubMed ID: 20684380)
1. [Analysis of direct costs during the treatment of tuberculosis in childhood].
Bodnár R; Mészáros A; Kádár L
Acta Pharm Hung; 2010; 80(2):67-73. PubMed ID: 20684380
[TBL] [Abstract][Full Text] [Related]
2. Cost analysis of paediatric tuberculosis treatment in Japan.
Rahman M; Takahashi O; Takamatsu I; Sekimoto M; Hira K; Fukui T
Int J Tuberc Lung Dis; 2003 Mar; 7(3):254-7. PubMed ID: 12661840
[TBL] [Abstract][Full Text] [Related]
3. Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.
Berman S; Rannie M; Moore L; Elias E; Dryer LJ; Jones MD
Pediatrics; 2005 Jun; 115(6):e637-42. PubMed ID: 15930189
[TBL] [Abstract][Full Text] [Related]
4. Cost of treatment for multidrug-resistant tuberculosis in South Korea.
Kang YA; Choi YJ; Cho YJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Respirology; 2006 Nov; 11(6):793-8. PubMed ID: 17052310
[TBL] [Abstract][Full Text] [Related]
5. How affordable are tuberculosis diagnosis and treatment in rural China? An analysis from community and tuberculosis patient perspectives.
Liu X; Thomson R; Gong Y; Zhao F; Squire SB; Tolhurst R; Zhao X; Yan F; Tang S
Trop Med Int Health; 2007 Dec; 12(12):1464-71. PubMed ID: 18076553
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of different types of tuberculosis patient at tuberculosis centers in Thailand.
Kamolratanakul P; Hiransuthikul N; Singhadong N; Kasetjaroen Y; Akksilp S; Lertmaharit S
Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):321-30. PubMed ID: 12236432
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries.
Hardy AB; Varma R; Collyns T; Moffitt SJ; Mullarkey C; Watson JP
Thorax; 2010 Feb; 65(2):178-80. PubMed ID: 19996345
[TBL] [Abstract][Full Text] [Related]
8. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
Pablos-Mendez A; Gowda DK; Frieden TR
Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
[TBL] [Abstract][Full Text] [Related]
9. Cost-comparison of different management policies for tuberculosis patients in Italy. AIPO TB Study Group.
Migliori GB; Ambrosetti M; Besozzi G; Farris B; Nutini S; Saini L; Casali L; Nardini S; Bugiani M; Neri M; Raviglione MC
Bull World Health Organ; 1999; 77(6):467-76. PubMed ID: 10427931
[TBL] [Abstract][Full Text] [Related]
10. Second-line drug resistance in multidrug-resistant tuberculosis cases of various origins in the Netherlands.
van Ingen J; Boeree MJ; Wright A; van der Laan T; Dekhuijzen PN; van Soolingen D
Int J Tuberc Lung Dis; 2008 Nov; 12(11):1295-9. PubMed ID: 18926040
[TBL] [Abstract][Full Text] [Related]
11. [Multidrug resistant tuberculosis in Iceland--case series and review of the literature].
Asgeirsson H; Blöndal K; Blöndal T; Gottfredsson M
Laeknabladid; 2009; 95(7-8):499-507. PubMed ID: 19553708
[TBL] [Abstract][Full Text] [Related]
12. [The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis].
Kizkin O; Hacievliyagil SS; Türker G; Günen H
Tuberk Toraks; 2003; 51(4):410-5. PubMed ID: 15143390
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. The societal cost of tuberculosis: Tarrant County, Texas, 2002.
Miller TL; McNabb SJ; Hilsenrath P; Pasipanodya J; Drewyer G; Weis SE
Ann Epidemiol; 2010 Jan; 20(1):1-7. PubMed ID: 20006270
[TBL] [Abstract][Full Text] [Related]
15. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis: cost of illness in Germany.
Diel R; Rutz S; Castell S; Schaberg T
Eur Respir J; 2012 Jul; 40(1):143-51. PubMed ID: 22267754
[TBL] [Abstract][Full Text] [Related]
17. Two simultaneous outbreaks of multidrug-resistant tuberculosis--Federated States of Micronesia, 2007-2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Mar; 58(10):253-6. PubMed ID: 19300407
[TBL] [Abstract][Full Text] [Related]
18. Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran.
Tabarsi P; Nooraki A; Mirsaeidi M; Amiri M; Baghaei P; Farnia P; Kazempour M; Heidarnazhad H; Alipanah N; Mansouri D; Masjedi MR
Respirology; 2008 Jan; 13(1):108-11. PubMed ID: 18197919
[TBL] [Abstract][Full Text] [Related]
19. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis.
Teixeira L; Perkins MD; Johnson JL; Keller R; Palaci M; do Valle Dettoni V; Canedo Rocha LM; Debanne S; Talbot E; Dietze R
Int J Tuberc Lung Dis; 2001 Apr; 5(4):321-8. PubMed ID: 11334250
[TBL] [Abstract][Full Text] [Related]
20. Health-care expenditures for tuberculosis in the United States.
Brown RE; Miller B; Taylor WR; Palmer C; Bosco L; Nicola RM; Zelinger J; Simpson K
Arch Intern Med; 1995 Aug 7-21; 155(15):1595-600. PubMed ID: 7618981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
